Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will ...

A German drugmaker best known for teaming with Pfizer to develop a Covid-19 vaccine is laying off dozens of employees at its ...

BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings ...

BioNTech hat vereinbart, den ehemaligen Corona-Impfstoffkonkurrenten CureVac für rund 1,25 Milliarden Dollar (1,08 Milliarden ...

BioNTech has agreed to acquire CureVac for approximately $1.25bn, as the former amps up its strategy to offer cancer ...